Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)

Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)

Abstract Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel resistance in STEMI patients undergoing PP...

Full description

Bibliographic Details
Main Authors: Renan Sukmawan, Erick Hoetama, Siska Suridanda Danny, Astuti Giantini, Erlin Listiyaningsih, Vidya Gilang Rejeki, Amir Aziz Alkatiri, Isman Firdaus
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Pharmacology Research & Perspectives
Subjects:
acute coronary syndrome
clopidogrel resistance
CYP2C19
DNA methylation
Online Access:https://doi.org/10.1002/prp2.738

Internet

https://doi.org/10.1002/prp2.738

Similar Items